Bernstein Reiterates Outperform Rating on Eli Lilly (LLY); 'Lilly's Tirzepatide is Officially "No Longer in Shortage"'
Tweet Send to a Friend
Bernstein SocGen Group analyst Courtney Breen reiterated an Outperform rating and $1,100.00 price target on Eli Lilly (NYSE: LLY).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
